INVESTOR ALERT: Investigation of MabVax Therapeutics Announced by Holzer & Holzer

ATLANTA--()--Holzer & Holzer, LLC is investigating whether MabVax Therapeutics Holdings, Inc. (“MabVax” or the “Company”) (NASDAQ: MBVX) complied with the federal securities laws. On January 30, 2018, MabVax announced that it received notice that the Securities and Exchange Commission (“SEC”) is investigating and examining certain of the Company’s filed registration statements and subsequent amendments. The price of MabVax stock fell significantly following the announcement.

If you purchased MabVax common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Alexandria P. Rankin, Esq. at arankin@holzerlaw.com, or call the firm by toll-free telephone at (888) 508-6832.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

Contacts

Holzer & Holzer, LLC
Corey D. Holzer, Esq., 888-508-6832
cholzer@holzerlaw.com

Release Summary

Holzer investigates MabVax

Contacts

Holzer & Holzer, LLC
Corey D. Holzer, Esq., 888-508-6832
cholzer@holzerlaw.com